Cortistatin

Overview

Cortistatin (CST) is a cortical neuropeptide identified in 1996 by Luis de Lecea, J. Gregor Sutcliffe, and colleagues during subtractive hybridization screens of rat cortical cDNA libraries for novel neuropeptide-encoding transcripts. The name reflects both its cortical enrichment and its sequence similarity to somatostatin: cortistatin shares 11 of its 14 C-terminal amino acids with somatostatin-14 and binds all five somatostatin receptor subtypes (SSTR1-5) with high affinity.

Despite this receptor overlap, cortistatin produces a physiological profile distinct from somatostatin. Most notably, intracerebroventricular cortistatin induces slow-wave sleep and antagonizes cortical activation induced by acetylcholine — effects not produced by somatostatin itself. The divergence appears to arise from cortistatin's additional binding to the mu-opioid receptor-related ghrelin receptor GHS-R1a and to the orphan receptor MrgX2, giving cortistatin a broader receptor repertoire.

Cortistatin is predominantly expressed in cortical GABAergic interneurons and in scattered neurons of the hippocampus. Beyond its central effects on sleep and cortical activity, cortistatin has emerged as an important peripheral anti-inflammatory and immunomodulatory peptide, with broad effects on macrophage function, T-cell responses, and models of autoimmune and inflammatory disease.

Structure/Sequence

Human cortistatin-17 (mature peptide): DRMPCRNFFWKTFSSCK (disulfide bridge Cys5-Cys16)

Rodent cortistatin-14: PCKNFFWKTFSSCK (disulfide bridge Cys2-Cys13)

Cortistatin-29: N-terminally extended form

• Species differences: Humans express CST-17 as the primary form; rodents express CST-14
• Disulfide bridge: Internal disulfide constrains the C-terminal pharmacophore, analogous to somatostatin
• Gene: CORT (human, chromosome 1p36.22)
• Shared motif with somatostatin: FWKT core essential for SSTR binding
• Distinguishing residues: N-terminal sequence and specific substitutions alter GHS-R1a binding and MrgX2 interaction

The FWKT "pharmacophore" is the canonical somatostatin receptor recognition element, conserved between cortistatin and somatostatin. Variations elsewhere in the sequence account for the differential binding to GHS-R1a.

Mechanism of Action

Somatostatin Receptor Activation

Cortistatin binds and activates all five SSTR subtypes with affinities similar to somatostatin:

• SSTR1-5: Gi/o-coupled; inhibit adenylyl cyclase, activate K+ channels, inhibit calcium channels
• Receptor occupancy produces classical somatostatin-like effects: suppression of GH and TSH, modulation of gastrointestinal motility, and inhibition of cortical excitability

Ghrelin Receptor (GHS-R1a) Binding

Cortistatin is the only known endogenous peptide besides ghrelin to bind GHS-R1a with high affinity. This places cortistatin at a cross-roads of the GH axis, where it could theoretically counter ghrelin's GH-releasing effects while also producing somatostatin-like GH suppression.

MrgX2 Binding

Cortistatin activates MrgX2 (MAS-related GPCR X2), a mast cell and sensory neuron receptor implicated in pseudo-allergic reactions and neuroimmune signaling. This interaction underlies some cortistatin anti-inflammatory effects.

Sleep and Cortical Effects

• Intracerebroventricular CST induces slow-wave (non-REM) sleep
• Enhances EEG synchrony and delta-wave activity
• Antagonizes acetylcholine-induced cortical activation
• Increases GABAergic tone in cortex
• Effects distinguish CST from somatostatin, which does not induce sleep

Anti-Inflammatory Effects

• Suppresses TNF-α, IL-6, IL-1β production in macrophages
• Reduces Th1 and Th17 responses
• Promotes T regulatory cell induction
• Protective in animal models of sepsis, colitis, arthritis, and multiple sclerosis
• Effects involve both SSTR and GHS-R1a signaling

Neuroprotection

CST attenuates excitotoxicity, reduces neuroinflammation, and protects neurons in cerebral ischemia models.

Research Summary

Common Discussion Topics

1. Shared receptors, different physiology — Cortistatin and somatostatin bind the same five SSTR subtypes yet produce different behavioral effects, most strikingly in sleep induction. This discrepancy is attributed to cortistatin's additional binding partners (GHS-R1a and MrgX2) and to different anatomical distributions of the two peptides.

2. Sleep neuropeptide — Among the endogenous "somnogenic" peptides, cortistatin stands alongside DSIP and adenosine derivatives. Its sleep-inducing profile specifically enhances slow-wave sleep, consistent with cortical GABAergic actions.

3. Therapeutic potential in autoimmunity — The combination of somatostatin-like immunomodulation plus ghrelin-receptor-mediated effects has made cortistatin a peptide of interest for autoimmune and chronic inflammatory models, with protective effects demonstrated across multiple disease paradigms.

4. Ghrelin receptor cross-talk — Cortistatin's GHS-R1a binding raises questions about how the brain integrates signals from two structurally distinct peptides converging on the same receptor. This cross-talk may be particularly relevant in the hypothalamus, where both peptides are expressed.

5. Evolutionary relationship — Cortistatin and somatostatin genes likely arose from a common ancestor through gene duplication. The degree of sequence and functional overlap versus divergence illustrates how neuropeptide systems elaborate through gene family expansion.

Related Compounds

• Somatostatin — the closely related peptide sharing SSTR pharmacology
• Ghrelin — canonical GHS-R1a agonist, partially overlapping with cortistatin
• Orexin-A — contrasting wake-promoting peptide from overlapping cortical-hypothalamic networks
• DSIP — delta sleep-inducing peptide with distinct structure